Abstract
Background: Cryptococcosis is an opportunistic infection with morbidity and mortality in HIV-infected patients. Impact of antiretroviral therapy (ART) on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcosis has not been well established. Methods: A retrospective cohort study of HIV-infected patients with cryptococcosis during 1997-2005 was conducted. Relapse and survival rates with corresponding risk factors were determined. Results: There were 149 patients with a mean age of 33.5±7.4 years and 57% were male. Median CD4 cell count was 22 cells/mm3. After exclusion of patients who died or were lost to follow-up during the first two weeks, 127 patients were eligible for the analysis of the effect of ART on relapse and survival rates. Of 127 patients, 52 received ART. The demographic data between the two groups were similar. Median time of ART initiation after cryptococcal diagnosis was 2.6 months. The most frequent ART used was NNRTI-based regimen (88.4%). Median CD4 change at six months of ART was 97 cells/mm3 and 87.9% achieved undetectable HIV-RNA. The cumulative 75% survival (free) from relapse duration was 10.4 months in no-ART group and 41.9 months in ART group (P < 0.01). The 75% survival from cryptococcal-related mortality in no-ART group was 6.4 months whereas > 54 months for ART group (P < 0.01). In Cox proportional hazards model, ART was the only factor that associated with lower relapse and mortality rate (P < 0.01). Conclusions: ART significantly reduced relapse and mortality rate from cryptococcosis in HIV-infected patients. ART is strongly recommended in this population and should not be delayed.
Keywords: HIV, antiretroviral therapy, cryptococcosis, survival, relapse
Current HIV Research
Title: Impact of Antiretroviral Therapy on the Relapse of Cryptococcosis and Survival of HIV-Infected Patients with Cryptococcal Infection
Volume: 5 Issue: 3
Author(s): Ubonvan Jongwutiwes, Sasisopin Kiertiburanakul and Somnuek Sungkanuparph
Affiliation:
Keywords: HIV, antiretroviral therapy, cryptococcosis, survival, relapse
Abstract: Background: Cryptococcosis is an opportunistic infection with morbidity and mortality in HIV-infected patients. Impact of antiretroviral therapy (ART) on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcosis has not been well established. Methods: A retrospective cohort study of HIV-infected patients with cryptococcosis during 1997-2005 was conducted. Relapse and survival rates with corresponding risk factors were determined. Results: There were 149 patients with a mean age of 33.5±7.4 years and 57% were male. Median CD4 cell count was 22 cells/mm3. After exclusion of patients who died or were lost to follow-up during the first two weeks, 127 patients were eligible for the analysis of the effect of ART on relapse and survival rates. Of 127 patients, 52 received ART. The demographic data between the two groups were similar. Median time of ART initiation after cryptococcal diagnosis was 2.6 months. The most frequent ART used was NNRTI-based regimen (88.4%). Median CD4 change at six months of ART was 97 cells/mm3 and 87.9% achieved undetectable HIV-RNA. The cumulative 75% survival (free) from relapse duration was 10.4 months in no-ART group and 41.9 months in ART group (P < 0.01). The 75% survival from cryptococcal-related mortality in no-ART group was 6.4 months whereas > 54 months for ART group (P < 0.01). In Cox proportional hazards model, ART was the only factor that associated with lower relapse and mortality rate (P < 0.01). Conclusions: ART significantly reduced relapse and mortality rate from cryptococcosis in HIV-infected patients. ART is strongly recommended in this population and should not be delayed.
Export Options
About this article
Cite this article as:
Jongwutiwes Ubonvan, Kiertiburanakul Sasisopin and Sungkanuparph Somnuek, Impact of Antiretroviral Therapy on the Relapse of Cryptococcosis and Survival of HIV-Infected Patients with Cryptococcal Infection, Current HIV Research 2007; 5 (3) . https://dx.doi.org/10.2174/157016207780636551
DOI https://dx.doi.org/10.2174/157016207780636551 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in people living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Applications of Choline PET/CT in Brain Tumors
Current Pharmaceutical Design Diagnosis and Treatment of Pulmonary Fungal Infections in Critically Ill Patients
Current Respiratory Medicine Reviews Coexistence of Large Meningioma and Arteriovenous Malformation: A Case Report and Literature Review
Current Medical Imaging Biomedical Technologies for In Vitro Screening and Controlled Delivery of Neuroactive Compounds
Central Nervous System Agents in Medicinal Chemistry A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem
Current Pharmaceutical Biotechnology Herbal Extracts with Antifungal Activity against Candida albicans: A Systematic Review
Mini-Reviews in Medicinal Chemistry Neuroleptic Malignant Syndrome: A Pilot Study on Psychiatric Inpatients in Iran
Current Psychopharmacology Antibiotic Properties and Applications of Lactoferrin
Current Pharmaceutical Design Vaccines and Neurological Disease
Current Pharmaceutical Design Immunopathological Aspects of Mycoplasma pneumoniae Infection
Current Pediatric Reviews AIDS-Defining Illnesses: A Comparison Between Before and After Commencement of Highly Active Antiretroviral Therapy (HAART)
Current HIV Research 5HT1F- and 5HT7-Receptor Agonists for the Treatment of Migraines
CNS & Neurological Disorders - Drug Targets Altering the Tropism of Lentiviral Vectors through Pseudotyping
Current Gene Therapy Diagnostic Value of the Leukocyte Esterase Test for Early Detection of Pleocytosis in Cerebrospinal Fluid of Patients with Suspected Acute Bacterial Meningitis
Infectious Disorders - Drug Targets The Role of Microbial Agents in the Etiology of Schizophrenia: An Infectious Hypothesis for Psychosis?
Current Immunology Reviews (Discontinued) Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Emerging Treatment Strategies
Current Pharmaceutical Biotechnology Mast Cell – Glia Dialogue in Chronic Pain and Neuropathic Pain: Blood-Brain Barrier Implications
CNS & Neurological Disorders - Drug Targets Dendrimers as Novel Systems for Delivery of Neuropharmaceuticals to the Brain
CNS & Neurological Disorders - Drug Targets Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry New Approaches in the Management of Septic Shock
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents